In one paragraphArticle in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
22 authors.
Caio César Barbosa Bomfim *Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.ORCID 0000-0003-1998-9237 Natacha Faivre *Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.ORCID 0009-0008-0330-5519 Thomas BenoistInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.ORCID 0000-0003-0116-2629 Manon PopisInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.
Bastien SuireInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.
David PericatInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.
José Manuel Sánchez-LópezInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.ORCID 0000-0002-1349-4746 Beatriz Melissa Aponte-CastilloUnidad de Investigación Médica en Genética Humana (UIMGH), Hospital de Pediatría Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, México.ORCID 0009-0004-5613-4718 Emmanuelle NäserInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.
Pénélope VianaInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.ORCID 0000-0003-0098-4831 Nicolas GuibertService de Pneumologie, Hôpital Larrey, CHU de Toulouse, Toulouse, France.
Romain VergéInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.
Julien MazièresService de Pneumologie, Hôpital Larrey, CHU de Toulouse, Toulouse, France.
Arnaud MétaisInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.ORCID 0000-0002-9538-0338 Renaud PoinclouxInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.ORCID 0000-0003-2884-1744 Brigitte Raynaud-MessinaInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.ORCID 0009-0000-1512-0871 Fabrice DumasInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.ORCID 0000-0002-9164-4527 Olivier NeyrollesInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.ORCID 0000-0003-0047-5885 Christel VérolletInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.ORCID 0000-0002-1079-9085 Etienne MeunierInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.ORCID 0000-0002-3651-4877 Geanncarlo Lugo-Villarino *Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.ORCID 0000-0003-4620-8491 Céline Cougoule *Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Toulouse, France.ORCID 0000-0002-6795-5448 Funding
Agence Nationale de Recherches sur le Sida et les Hépatites Virales 2022-ECTZ190463, 2022-ECTZ205302, 2023-ECTZ293306Bill and Melinda Gates Foundation INV-046428Fondation pour la Recherche Médicale EQU202303016313H2020 Health 101080462Sidaction 22-2-AEQ-13457-1UK Research and Innovation 101080462
6 · The paper itselfAbstract
Tuberculosis (TB) remains a major global health challenge that requires new therapeutic strategies to improve drug efficacy, shorten treatment duration, prevent drug resistance, and limit IMPORTANCE: Tuberculosis remains one of the world's deadliest infectious diseases. The development of new therapies is limited by the absence of human-relevant models that reproduce the distinct lung niches encountered by
Indexed as
Antitubercular AgentsHost-Directed TherapyLungMacrophages, AlveolarMycobacterium tuberculosisTuberculosisCells, CulturedHumansTuberculosis, PulmonaryAntitubercular Agentsair–liquid interface culturesalveolar macrophagesantibioticsantimicrobial efficacyhost-directed therapyMycobacterium tuberculosis
Identifiers
PMID42112802
PMCPMC13227965
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390